Thyroid Disease Diagnosis and Treatment Center, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650031, Yunnan, China.
Endocr Pathol. 2015 Mar;26(1):21-6. doi: 10.1007/s12022-015-9356-9.
The incidence of thyroid cancer has appeared as an increasing trend globally, especially in Asian countries. In this study, the expression of mucin-1 (MUC1) and Thomsen-Friedenreich antigen, Galβ1-3GalNAcα1-R (CD176) was investigated by immunohistochemistry in papillary thyroid carcinomas (PTCs), which accounts for approximately 80 % of all thyroid cancer. We found that 78 % of PTC overexpressed MUC1. Importantly, we observed firstly that CD176 was expressed in 63 % of PTC, but was faintly or not expressed in normal thyroid tissues and benign thyroid disease tissues, indicating that CD176 is also a tumour-associated antigen for PTCs. Moreover, expression of CD176 was strongly correlated with MUC1 by immunohistochemical staining in PTCs. Furthermore, we used the immunochemical method to confirm that MUC1 is a common and main carrier of CD176 in PTCs. Our data demonstrated that MUC1 and CD176 might be promising biomarkers for thyroid cancer.
甲状腺癌的发病率在全球范围内呈现出上升趋势，尤其在亚洲国家更为明显。本研究通过免疫组织化学方法检测了约占所有甲状腺癌 80%的甲状腺乳头状癌（PTC）中黏蛋白 1（MUC1）和 Thomsen-Friedenreich 抗原、Galβ1-3GalNAcα1-R（CD176）的表达。我们发现 78%的 PTC 过度表达 MUC1。重要的是，我们首次观察到 CD176 在 63%的 PTC 中表达，但在正常甲状腺组织和良性甲状腺疾病组织中表达微弱或不表达，表明 CD176 也是 PTC 的肿瘤相关抗原。此外，在 PTC 中，CD176 的表达与 MUC1 的免疫组织化学染色呈强相关性。此外，我们还使用免疫化学方法证实 MUC1 是 PTC 中 CD176 的常见和主要载体。我们的数据表明，MUC1 和 CD176 可能是甲状腺癌有前途的生物标志物。
